- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Sclerosing agents.
Displaying page 1 of 1.
EudraCT Number: 2014-002393-37 | Sponsor Protocol Number: RG_13-027 | Start Date*: 2015-01-06 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A single arm, two-stage, multi-centre, phase II clinical trial investigating the safety and activity of the use of BTT1023, a human monoclonal antibody targeting vascular adhesion protein (VAP-1), ... | |||||||||||||
Medical condition: Primary Sclerosing Cholangitis (PSC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002473-61 | Sponsor Protocol Number: GS-US-321-0102 | Start Date*: 2013-05-08 | |||||||||||
Sponsor Name:Gilead Sciences Inc | |||||||||||||
Full Title: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects wi... | |||||||||||||
Medical condition: Primary Sclerosing Cholangitis (PSC) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) SE (Completed) IT (Completed) DK (Completed) ES (Completed) BE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001428-33 | Sponsor Protocol Number: PLN-74809-PSC-203 | Start Date*: 2020-11-05 | |||||||||||
Sponsor Name:Pliant Therapeutics, Inc | |||||||||||||
Full Title: A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with primary sclerosing cholangitis ... | |||||||||||||
Medical condition: Primary sclerosing cholangitis (PSC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) BE (Completed) FR (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000621-27 | Sponsor Protocol Number: RTRX-RE021-201 | Start Date*: 2022-10-20 | |||||||||||||||||||||||||||||||
Sponsor Name:Travere Therapeutics, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases (E... | |||||||||||||||||||||||||||||||||
Medical condition: Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Al... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Completed) ES (Temporarily Halted) SE (Trial now transitioned) PL (Temporarily Halted) DE (Restarted) IT (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
